The goal of this proposal is to develop a "loading dose" approach to starting methadone to treat fentanyl opioid use disorder (OUD). We aim to conduct an assessor-blinded dose-finding study of 24 participants with fentanyl OUD recruited to a research unit for monitored methadone dosing. Participants will be randomized to standard methadone initiation vs. one of three loading dose approaches. The primary goal is to identify the maximum tolerated methadone loading dose appropriate for future study.

开始日期2025-09-01

申办/合作机构

University of Pennsylvania

NCT06940570

/ Not yet recruiting临床3期IIT

A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant). The chemotherapy will kill cancer cells, but good cells, such as those in the mouth, are killed too. The mouth cells going away causes the areas in the mouth to be blistered, irritated, sore, and extremely painful. Pain medication (usually morphine or hydromorphone if allergic to morphine) are given when oral blisters are seen or felt by patient in patient's mouth. However, one pain medication given through a vein in the patient may or may not be effective and providers are often challenged with providing good pain control while waiting for the new donor cells to grow, which will then heal the mouth. This is a period of waiting that is 6-8 weeks.
The investigators know that methadone, a second pain medication, may decrease pain in a different way than morphine. This is because methadone works in a different way in the brain than morphine. By giving these pain medicines together, the hope of the study is to show decreased pain while waiting for new cells to grow.
The goal of this clinical trial is to hope to learn whether adding methadone (second pain medication) to the current pain medication which is morphine alone (all patients will receive this pain medication) will help reduce the pain experience of participant. Current treatment of morphine alone is sometimes not entirely effective and so any improvement of pain while waiting for new cells to grow is one of the goals of this study. If methadone is effective in decreasing pain, then patients may benefit in the future from using these two medications up front when getting a transplant.
Participant in this study between 6-18 years of age and is needing a stem cell transplant for a disease that can potentially be cured by transplantation.
Participant in this study is receiving chemotherapy and/or radiation conditioning that can cause mucositis. Participants are being asked to participate in this study because participants meet criteria to receive methadone that may or may not reduce pain experience versus just being given morphine alone, which is what all patients are given when the participants have mucositis.
The main goal of the study is to see if less opioid (pain medication) when methadone is added in comparison to participant who uses PCA only. The investigators also want to learn if patient's overall function is improved if given methadone. Another goal would be to see the number of TPN days the participant received and if the participant who was given methadone began to eat sooner. Other smaller goals include learning about side effects of methadone, and if the hospital stay is less for those who receive the study medication.
This medication will be given at Children's Medical Center of Dallas while participant is admitted for the stem cell transplant. There is no sponsor that is funding the study and this drug will be given free of charge in exchange for participation in the study

开始日期2025-08-01

申办/合作机构

The University of Texas Southwestern Medical Center

CTRI/2025/03/082707

/ Not yet recruiting临床4期IIT

Evaluating the efficacy of combination of low dose Methadone with Morphine vs Morphine for pain management in Gastrointestinal cancers- a Randomised Control Trial - NIL

开始日期2025-06-01

申办/合作机构-

100 项与盐酸美沙酮相关的临床结果

登录后查看更多信息

100 项与盐酸美沙酮相关的转化医学

登录后查看更多信息

100 项与盐酸美沙酮相关的专利（医药）

登录后查看更多信息

20,292

项与盐酸美沙酮相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China

Article

作者: Gao, Linying ; Men, Zhaoyue ; Xue, Tongchuan ; Liang, Xiaofeng ; Yao, Tian ; Feng, Yongliang ; Wang, Suping ; Yuan, Yuan ; Gao, Yizhuo ; Liu, Yuan ; Wang, Fuzhen ; Mo, Xinyuan ; Wang, Keke

CLINICAL TRIAL REGISTRATIONClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816.

2025-12-01·European Journal of Trauma and Emergency Surgery

Pre-injury narcotic drug use in isolated severe traumatic brain injury: effect on outcomes

Article

作者: Abe, Takeru ; Yamaguchi, Keishi ; Demetriades, Demetrios ; Takahashi, Kyosuke ; Jakob, Dominik Andreas ; Matsushima, Kazuhide

PURPOSEThe aim of this study was to explore the association between pre-injury narcotic drug use (opioids, methadone, and/or oxycodone) and outcomes in isolated severe traumatic brain injury (TBI) patients.METHODSACS TQIP study included adult trauma patients (≥ 16 years) with complete drug and alcohol screening. Isolated severe TBI was defined as head trauma with AIS 3-5 and without significant extracranial trauma. Exact matching was used to compare patients with isolated pre-injury narcotic drug use to those with no illicit drug or alcohol use. Patients were matched 1:1 based on the following matching criteria: age, gender, mechanism of injury, Injury Severity Score, systolic blood pressure, head AIS, and comorbidities.RESULTSOf 1,846,630 patients, 141,058 had isolated severe head injuries with complete drug and alcohol screenings. After exact matching, 1,560 patients in each group were analyzed. There were no significant differences in hospital mortality, craniectomy rates, complication rates, or length of hospital stay. Patients that tested positive for narcotics had lower rates of mechanical ventilation (16.5% vs. 25.3%, p < 0.01) and shorter ICU stays [3 (2-4) days vs. 3 (2-6) days; p < 0.01].CONCLUSIONPre-injury narcotic drug use in isolated severe TBI is not associates with adverse outcomes. Further research is needed to understand the biochemical and physiological effects of narcotic drugs on TBI outcomes.

2025-07-01·Water Research

Do suspended particles matter for wastewater-based epidemiology?

Article

作者: Bernier-Turpin, Gauthier ; Alliot, Fabrice ; Guérin-Rechdaoui, Sabrina ; Thiebault, Thomas ; Cenik, Chloé ; Moilleron, Régis

As wastewater-based epidemiology (WBE) continues to evolve and expand the range of targeted compounds, some limitations remain underexplored, particularly the sorption of targeted markers onto suspended particulate matter (SPM) in raw wastewater. This issue is crucial as it could lead to underestimations in retrospective calculations. While previous studies have addressed this topic, they have primarily focused on a limited range of analytes (e.g., illicit drugs and selected pharmaceuticals) and relied on small sample sizes, highlighting the need for further research. This study aims to bridge these gaps through a six-month monitoring campaign analyzing a broad range of WBE markers (pharmaceuticals, illicit drugs, and lifestyle biomarkers) in both the dissolved and the particulate phases. A dedicated analytical method based on pressurized liquid extraction and liquid chromatography coupled with tandem mass spectrometry allowed the assessment of daily loads and distribution behavior of these compounds, providing new insights into their relevance for WBE estimates. The results demonstrated that most compounds exhibited low sorption to SPM, confirming their reliability for WBE monitoring based solely on dissolved-phase measurements. Notably, this study provides the first clear assessment of the minimal sorption of tobacco and coffee biomarkers. However, significant sorption was observed for 11 molecules, including fluoxetine, THCCOOH, and methadone, revealing a "hidden load" that could bias estimates without proper correction. Log D proved to be a useful and better than log Kow predictor of sorption potential for ionized compounds but failed to accurately predict sorption for neutral species. Additionally, wastewater dilution due to urban runoff appeared to influence compound partitioning, potentially increasing their affinity for the solid phase. Nonetheless, potential changes in the organic composition of SPM do not appear to be the driving factor, as the studied material retained stable total organic carbon (TOC) levels, most likely due to in-sewer remobilization of organic deposits which share a similar signature with domestic wastewater effluent. Further investigations are needed to identify the key parameters influencing compound affinity for SPM and their potential implications for WBE applications.

143

项与盐酸美沙酮相关的新闻（医药）

2025-04-23

·ir.ensysce.com

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof¹ including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce's TAAPTM and MPAR® abuse deterrent and overdose protection technologies. Methadone has long been a cornerstone treatment for OUD, but its use has been limited by concerns over cardiac side effects, respiratory depression, and risk of overdose. Ensysce has developed a new class of agents for the treatment for OUD in the form of PF9001. This new drug is a significant advancement in the treatment of OUD, with data demonstrating a reduction in potential for cardiotoxicity, validating MPAR® overdose protection, and indications of potentially delivering a prolonged and predictable effect following once daily dosing. Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Center who specializes in emergency medicine and toxicology commented, "Novel agents for the treatment of OUD are needed. The MPAR technology applied to methadone analogues has the potential to save lives by reducing overdose." Dr. Lynn Kirkpatrick, CEO of Ensysce, added, "PF9001 and this approach is the result of years of dedicated research focused on providing safer medications for the treatment of OUD while reducing the risks associated with its therapy. Our novel TAAP and MPAR technology offers patients and providers a safer, more tolerable alternative to current therapy which has been recognized with financial support provided by the National Institute on Drug Abuse. We believe PF9001 could potentially increase treatment adherence and improve outcomes for OUD patients." ¹The research covered by this patent was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number UG3DA050271. About Ensysce Biosciences Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com. Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-K and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196 Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ North America Main: 203-741-8811 ENSC@mzgroup.us SOURCE: Ensysce Biosciences Inc. Released April 23, 2025

2025-04-13

·MedCity News

Stigma Against Addiction Medication Limits Our Ability to End the Opioid Epidemic - MedCity News

Some of the most recently available data brings welcome news in the nationwide fight against the opioid epidemic. After many months of increasing overdose deaths in the wake of the Covid pandemic – a period of loneliness and struggle for many Americans – we appear to be turning the tide. Data from the Centers for Disease Control and Prevention show that overdose deaths peaked in August 2023, but in the twelve months since that time, there was a reduction in the number of drug-overdose deaths by about one sixth. This is an encouraging trend. But even with the significant reduction, we must still reckon with the fact that 90,000 Americans lost their lives to opioid addiction during that period. That’s about the population of Santa Barbara, California. While the change in the trajectory of deaths from overdose is positive, we still have much to do to further reduce addiction, overdoses, and deaths. presented by Sponsored Post What Are the Best Medical Coding Outsourcing Companies? Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you. By Global Healthcare Resources Critical to continuing this progress is making sure those in need can access effective opioid treatment programs, like those that incorporate medication for opioid use disorder (MOUD). The three FDA-approved medications for opioid use disorder are buprenorphine, methadone, and naltrexone – all of which have been proven safe and effective. These medications, considered the gold-standard treatment, help patients prevent or reduce overdoses by relieving withdrawal symptoms and cravings. In one representative example of the scientific literature on MOUD, a National Institutes of Health-funded study found that methadone helped adults struggling with addiction decrease the risk of overdose deaths by 59 percent. Though MOUD can be significantly helpful in curbing overdoses, patients are unlikely to yield maximum effectiveness unless it is combined with the personalized care offered through counseling. Sponsored Post Changes in Nurse Staffing Answer Clinician Demands The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want. By Tomasz Rezik The Substance Abuse and Mental Health Services Administration tells us that this combination offers a “whole-patient” approach that helps people overcome substance use disorders and sustain recovery. Expert consensus on the efficacy of this approach is why federal law requires opioid treatment programs to offer counseling. But despite the decline in overdose deaths, there seems to be a stagnation in wider acceptance of MOUD. Even as studies and personal experiences repeatedly reflect the effectiveness of MOUD, a stigma about this approach and the medication persists, complicating efforts to help more people treat their opioid use disorders. This stigma often arises from the fact that methadone and buprenorphine activate receptors in the brain similarly to opioids. The difference is that these medications activate receptors more slowly and, for opioid-dependent people, in a way that produces no euphoria. It’s what allows patients to continue recovery with a much smaller likelihood of relapsing. These characteristics of the medication cause some in the treatment ecosystem to mistakenly view MOUD as hardly better than heroin itself. Proponents of this viewpoint make misleading claims, such as that using MOUD is merely substituting one opioid for another. For some folks, complete abstinence – including from MOUD – is the only appropriate treatment option, despite the much higher risk for overdosing. Some organizations, including Narcotics Anonymous chapters and Salvation Army facilities, discourage or bar members from using MOUD, treat members who use MOUD as inferior, and sometimes even ask members not to return if they are using MOUD. Other patients encounter detox facilities, sober living homes, and rehab centers that reject this vital resource for treating addiction. This failure to make MOUD accessible is disturbingly prevalent. A 2023 federal government survey found that over 40 percent of more than 14,000 treatment facilities did not offer methadone or buprenorphine. The rejection of MOUD is a tragic misunderstanding of effective medication that results in avoidable overdoses instead of improved health outcomes. Policymakers should ensure that taxpayer-funded efforts to make treatment more accessible support opioid treatment programs that offer the proven benefits of MOUD and counseling. Additionally, professionals in the addiction field should take every opportunity to combat the harmful stigma against MOUD and reinforce its ability to help patients recover. The opioid epidemic is showing signs of waning. If we are to continue this progress, we must do a better job of embracing effective treatment and fighting dangerous stigmas. When we are facing an epidemic as widespread and lethal as opioid addiction, we should utilize all the tools we have available to save lives and preserve individuals.

2025-04-10

·PRNewswire

Newborn Brains Are Smaller When Exposed to Opioids During Gestation

An important "first dive" into data from the 4-site Outcomes of Babies with Opioid Exposure (OBOE) study features a Cincinnati Children's expert as co-first author CINCINNATI, April 10, 2025 /PRNewswire/ -- When pregnant women take opioids during pregnancy, even opioids such as buprenorphine or methadone to treat opioid use disorder, the developing brains of their children can be significantly affected, according to a study published April 7, 2025, in JAMA Pediatrics. Continue Reading Antenatal opioid exposure is associated with smaller neonatal brain volumes, with varying impact depending on the type and number of exposures, according to research published in JAMA Pediatrics. Stephanie Merhar, MD, MS, at Cincinnati Children's was first co-author. Total brain volume was nearly 5% smaller among 173 newborns with antenatal opioid exposure compared to 96 unexposed newborns, based on magnetic resonance imaging (MRI) scans. More specifically, reduced volumes among opioid-exposed newborns occurred in cortical gray matter, deep gray matter, white matter, cerebellum, brainstem, and the right and left amygdala. There were notable differences in the location and scale of the effects, which varied depending on the type of opioid involved, and whether other drugs were also taken during pregnancy. "We have known for a while that children exposed to opioids during pregnancy are at risk of later developmental and behavioral problems, but it was hard to know whether that was due to the opioids themselves or other factors such as other exposures or lower birth weight," says co-first author Stephanie Merhar, MD, MS, a neonatologist at Cincinnati Children's. "This study was launched because we needed a large study where we were able to control for things like nicotine exposure and birth weight. Our next step is to follow the children in the study to see whether having smaller brain volumes in the newborn period affects later development and behavior." The double-threat opioids pose to mothers and children Nearly 1 in 12 newborns in the United States in 2020 – or about 300,000 infants – were exposed to alcohol, opioids, marijuana or cocaine before they were born, according to the Substance Abuse and Mental Health Services Administration (SAMHSA). Prenatal substance exposure in rural areas often exceeds overall national averages. Opioids include illegal drugs like heroin and fentanyl, prescription drugs like oxycodone and hydrocodone, and medications for opioid use disorder like buprenorphine and methadone. Opioid use often goes hand in hand with smoking and use of other substances such as alcohol and marijuana. This study compared newborns born to mothers who took opioids only and newborns born to mothers who used other substances as well as opioids. Newborns exposed to opioids plus other substances had smaller brain volumes in more regions compared to those exposed to opioids only. The most common opioids among participants in the new study were buprenorphine (68.8%) and methadone (26%). Both of these opioids are routinely used to treat opioid use disorder (OUD) and are both recommended for treatment of OUD during pregnancy by the American College of Obstetricians and Gynecologists. "We know that buprenorphine and methadone are life-saving medications for women with OUD," Merhar says. "We don't want to imply that women with OUD should wean off these medications, but we agree with the ACOG recommendation for more research on medically supervised withdrawal in pregnant women." The study was praised in an accompanying editorial penned by Nethra Madurai, MD, and Lauren Jantzie, PhD, both of Johns Hopkins University School of Medicine. Other small studies have shown fetal brain changes caused by opioids. But this multi-center study is the first to be large enough to convincingly distinguish effects linked to opioids versus confounding factors such as maternal smoking, birth weight, education levels. The study authors "present compelling evidence of the direct effects of opioids on the developing brain," the editorial states. "Given the prospective design of the trial, they account for other postnatal factors…allowing us to dispel previous uncertainty surrounding the direct impacts of opioids on the brain vs the confounding effects of other environmental factors." What's next? Having more precise information about the affected parts of the brain could allow scientists to focus on interventions to support healthy brain development for children born after opioid exposure. "Indeed, we must shift our focus beyond the initial withdrawal symptoms associated with POE [prenatal opioid exposure] if we are to improve the lifelong health and well-being of infants and children impacted by the opioid epidemic," the editorial states. Read more about Merhar's research related to opioid exposure: 'Eat, Sleep, Console' Approach Slashes ICU Stays for Opioid-Exposed Newborns In Utero Opioid Exposure Impacts Fetal Brain Size and Development $8M Grant Funds Long-Term Opioid Exposure Study SOURCE Cincinnati Children's Hospital Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与盐酸美沙酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02102	盐酸美沙酮	N07BC02	DB00333

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癌症疼痛	日本	Shionogi & Co., Ltd.	2013-03-01
阿片相关性障碍	中国	Central Pharmaceutical JSC No. 3	1997-01-01
阿片滥用	美国	Hikma Pharmaceuticals USA, Inc.	1973-03-14
心理症状行为强迫行为成瘾	美国	SpecGx LLC	1973-03-14
心理症状行为强迫行为成瘾	美国	Hikma Pharmaceuticals USA, Inc.	1973-03-14
鸦片依赖	美国	Mylan Institutional LLC	1947-08-13
疼痛	美国	Mylan Institutional LLC	1947-08-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性神经病变	临床前	-	Methapharm, Inc.	2012-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04214834 (CTgov)	临床3期	新生儿戒断综合征	189	methadone+morphine (Rapid Wean)	淵衊網廠獵鹽憲築鏇鏇(積淵鬱廠壓選淵窪襯遞) = 餘廠繭網鏇製壓遞糧鹹膚壓憲願夢齋膚淵鬱築 (艱選鏇淵憲膚衊顧襯窪, 願遞網築願蓋顧觸顧鏇 ~ 積醖積壓鹹獵鏇選築夢) 更多	-	2025-03-13
				methadone+morphine (Slow Wean)	淵衊網廠獵鹽憲築鏇鏇(積淵鬱廠壓選淵窪襯遞) = 鏇積構窪鑰蓋鬱繭觸範膚壓憲願夢齋膚淵鬱築 (艱選鏇淵憲膚衊顧襯窪, 齋憲窪糧憲醖衊憲糧夢 ~ 網蓋鏇壓齋鹽範簾繭窪) 更多
NCT05425420 (MTH02, CTgov)	临床1/2期	术后疼痛	22	Methadone	齋鹽壓選鑰齋遞範淵窪(築顧糧鹹蓋選鬱鹽顧壓) = 窪顧製簾繭範鏇選廠顧網鑰製齋製衊醖顧糧鑰 (繭窪醖積餘願製構糧夢, 觸鏇鏇鹽餘壓艱範遞築 ~ 衊廠齋醖蓋積網鑰餘淵) 更多	-	2025-02-10
Pubmed \| Anesthesiology	N/A	-	60	Methadone 0.1 mg/kg	膚淵襯淵積醖願簾餘膚(壓夢衊艱範觸醖糧製醖) = 鹽鹽襯淵廠蓋齋憲鹽廠衊製襯夢繭襯鹽獵簾膚 (觸鏇壓繭膚膚鑰鬱艱鏇, 0.1 ~ 1.4)	积极	2024-09-01
				Methadone 0.15 mg/kg	膚淵襯淵積醖願簾餘膚(壓夢衊艱範觸醖糧製醖) = 願製醖餘鬱繭衊膚願製衊製襯夢繭襯鹽獵簾膚 (觸鏇壓繭膚膚鑰鬱艱鏇, 0 ~ 1.4)
NCT03033732 (Pubmed \| HIV Med)	临床4期	阿片滥用	272	Methadone	顧範顧獵襯夢鑰鑰簾糧(膚鏇廠築鹽憲餘構簾簾) = 艱蓋範廠積醖製願窪顧襯壓衊鹹衊鬱繭顧願鏇 (夢鏇積簾選窪餘願廠憲 ) 更多	积极	2024-07-01
				Buprenorphine/naloxone	顧範顧獵襯夢鑰鑰簾糧(膚鏇廠築鹽憲餘構簾簾) = 遞積艱壓鹹願範鬱齋淵襯壓衊鹹衊鬱繭顧願鏇 (夢鏇積簾選窪餘願廠憲 ) 更多
ENDO2024	N/A	终末期肾脏病	-	Methadone 110 mg daily	簾積蓋獵鹽顧製蓋觸網(製鹹鹹艱窪醖淵製夢獵) = Methadone induced hypoglycemia 獵網壓築鹹衊遞積淵鹽 (襯夢壓夢鬱製廠膚觸選 )	-	2024-06-01
ENDO2024	N/A	高胰岛素血症	-	Methadone	觸積窪範衊鹽構膚築築(構遞網齋鹽鹹襯衊製網) = 獵糧壓淵簾鹽鏇窪衊衊淵齋艱選淵願構憲蓋鹽 (膚齋窪窪艱鹽艱夢製鑰, 0.5 ~ 3.3) 更多	-	2024-06-01
NCT03033732 (Pubmed \| Can J Psychiatry) 人工标引	临床4期	阿片滥用	268	methadone or buprenorphine/naloxone	-	不佳	2024-03-01
				Methadone Maintenance Therapy (MMT)	積鬱醖窪製遞憲醖築繭(蓋壓鹽鹹遞鹹艱範製鹹) = 夢鬱築鹹餘糧鏇醖夢夢鹹夢淵願製觸蓋遞築廠 (壓鏇鑰網鹽鹽壓積蓋夢 ) 更多
NCT02252432 (CTgov)	临床4期	术后疼痛	13	methadone+Ketamine (Ketamine)	壓襯鹽膚壓築膚醖製顧(網網顧膚憲糧糧廠製願) = 憲觸醖鹽廠艱築選願壓襯願構鏇遞鏇鹽鏇選膚 (觸廠鬱願觸鏇廠簾獵繭, 鏇簾廠憲鹹願鹹築淵繭 ~ 醖醖簾遞鬱願鏇壓築繭) 更多	-	2024-02-29
				methadone+ketamine (Methadone)	壓襯鹽膚壓築膚醖製顧(網網顧膚憲糧糧廠製願) = 窪築糧製襯顧獵鹽艱鬱襯願構鏇遞鏇鹽鏇選膚 (觸廠鬱願觸鏇廠簾獵繭, 顧夢壓壓築蓋膚襯鹽鹹 ~ 餘鬱鏇鏇鹹淵餘淵憲顧) 更多
EUCTR2018-004351-20-DK \| NCT03908060 (Pubmed)	临床4期	-	-	Methadone 0.2 mg/kg	(觸醖衊選窪艱蓋獵遞網) = 夢築鹹襯艱顧遞壓簾襯壓積鹽鑰構獵醖襯遞夢 (窪鏇積襯鹹積齋範顧淵 )	-	2023-09-01
				Morphine 0.2 mg/kg	(觸醖衊選窪艱蓋獵遞網) = 夢蓋選齋艱簾鏇築鏇鹽壓積鹽鑰構獵醖襯遞夢 (窪鏇積襯鹹積齋範顧淵 )
NCT02851303 (CTgov)	临床4期	新生儿戒断综合征	61	Morphine (Morphine)	(簾艱鏇衊顧壓範窪廠餘) = 鬱齋積遞鏇膚鹽餘齋願簾製積糧壓淵顧範餘築 (艱鏇選鹽壓獵築鏇製醖, 製鏇鏇築鑰鹹鹽顧鹽壓 ~ 選選窪積鑰鬱遞積鑰觸) 更多	-	2023-05-24
				Methadone (Methadone)	(簾艱鏇衊顧壓範窪廠餘) = 簾遞簾蓋壓觸壓鏇壓製簾製積糧壓淵顧範餘築 (艱鏇選鹽壓獵築鏇製醖, 壓鹹網襯選鏇壓膚獵簾 ~ 膚憲築憲積鏇鏇淵壓襯) 更多